Jump to content
Wikipedia The Free Encyclopedia

KCNH1

From Wikipedia, the free encyclopedia
Protein-coding gene in the species Homo sapiens
KCNH1
Available structures
PDB Ortholog search: PDBe RCSB
List of PDB id codes

5J7E

Identifiers
Aliases KCNH1 , EAG, EAG1, Kv10.1, h-eag, TMBTS, ZLS1, hEAG1, potassium voltage-gated channel subfamily H member 1, hEAG
External IDsOMIM: 603305; MGI: 1341721; HomoloGene: 68242; GeneCards: KCNH1; OMA:KCNH1 - orthologs
Gene location (Human)
Chromosome 1 (human)
Chr. Chromosome 1 (human) [1]
Band 1q32.2Start210,676,823 bp [1]
End211,134,165 bp [1]
Gene location (Mouse)
Chromosome 1 (mouse)
Chr. Chromosome 1 (mouse)[2]
Band 1|1 H6Start191,873,082 bp [2]
End192,192,467 bp [2]
RNA expression pattern
Bgee
Human Mouse (ortholog)
  • Brodmann area 9

  • prefrontal cortex

  • testicle

  • right frontal lobe

  • cerebellar hemisphere

  • right hemisphere of cerebellum

  • cingulate gyrus

  • anterior cingulate cortex

  • caudate nucleus

  • gonad
  • secondary oocyte

  • epithelium of lens

  • olfactory tubercle

  • zygote

  • primary oocyte

  • primary motor cortex

  • nucleus accumbens

  • molar

  • lumbar spinal ganglion

  • superior frontal gyrus
More reference expression data
BioGPS
Gene ontology
Molecular function
Cellular component
Biological process
Sources:Amigo / QuickGO
Orthologs
SpeciesHumanMouse
Entrez

3756

16510

Ensembl

ENSG00000143473

ENSMUSG00000058248

UniProt

O95259

Q60603

RefSeq (mRNA)

NM_002238
NM_172362

NM_001038607
NM_010600

RefSeq (protein)

NP_002229
NP_758872

NP_001033696
NP_034730

Location (UCSC)Chr 1: 210.68 – 211.13 Mb Chr 1: 191.87 – 192.19 Mb
PubMed search[3] [4]
Wikidata

Potassium voltage-gated channel subfamily H member 1 (KV10.1, EAG1) is an ion channel protein that in humans is encoded by the KCNH1 gene.[5] [6] [7] Disease-causing (pathogenic) mutations in the KCNH1 gene cause KCNH1-related disorders, which can include symptoms such as mild-to-severe developmental delay, profound intellectual disability, neonatal hypotonia, myopathic facial appearance, and infantile-onset seizures. Aberrant overexpression of KCNH1 is associated with tumor progression.

Function

[edit ]

Expression of KCNH1 is predominantly restricted to the adult central nervous system.[8] The KCNH1 gene encodes a homotetrameric highly-conserved voltage-gated potassium channel (KV10.1) thought to be responsible for reestablishing the membrane potential of excitatory neurons in response to high frequency firing.[9]

KV10.1 is a non-inactivating delayed rectifier potassium channel. Like other voltage-gated potassium ion channels, opening of the KV10.1 channel pore is triggered by membrane depolarisation, which results in an outward flow of potassium ions to rectify the baseline membrane potential. KV10.1 is slow to open when triggered and does not undergo an inactivation state after closing.

Structurally, KV10.1 is composed of four identical subunits that are each 989 residues long (111.4 kDa). Each subunit is composed of a PAS domain, transmembrane voltage-sensing and pore domains, a C-linker, and an intracellular cyclic nucleotide-binding homology domain. Alternative splicing of this gene results in two transcript variants encoding distinct isoforms that differ by the inclusion or exclusion of 27 amino acids between the S3 and S4 helices of the voltage-sensing domain.[7]

KCNH1 expression is activated in cilia at the onset of myoblast differentiation and known to play roles in the cell cycle and cell proliferation.[10]

Pathologies

[edit ]

Gabbett and colleagues described Temple–Baraitser syndrome (TBS) in 2008, naming the condition after English clinical geneticists Profs Karen Temple and Michael Baraitser.[11] TBS is categorized by intellectual disabilities, epilepsy, atypical facial features, and aplasia of the nails. It was later demonstrated that de novo missense mutations in the KCNH1 gene cause deleterious gain of function in the voltage-gated potassium channel KV10.1, resulting in TBS.[12] Patients with de novo mutations in KCNH1 were found to be affected by epilepsy (without association to TBS), while children born with germline mutations from mosaic probands were affected by TBS.[12] This provides further evidence of the role that genetic mosaicism plays in the etiology of neurological disorders.

Type 1 Zimmermann–Laband syndrome was later found to be caused by similar missense mutations in KCNH1.[13] This has led some researchers to believe that type 1 Zimmermann-Laband and Temple-Baraitser syndromes are different manifestations of the same disorder.[14] [15] Current views are that Zimmermann-Laband and Temple-Baraitser syndromes are part of the greater spectrum of KCNH1-related disorders, which encompass a continuum of severity for mild to severe developmental delay, profound intellectual disability, neonatal hypotonia, myopathic facial appearance, and infantile-onset seizures.[16]

KCNH1 in cancer

[edit ]

Overexpression of KCNH1 may confer a growth advantage to cancer cells and favor tumor cell proliferation, as KCNH1 overexpression has been observed in 70% of solid tumors.[17] Individuals with missense mutations in KCNH1 have not reported any increase in incidence of cancers.

Interactions

[edit ]

KCNH1 has been shown to interact with KCNB1 [18] and is inhibited by the highly-conserved secondary messenger calmodulin in the presence of calcium.

See also

[edit ]

References

[edit ]
  1. ^ a b c GRCh38: Ensembl release 89: ENSG00000143473Ensembl, May 2017
  2. ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000058248Ensembl, May 2017
  3. ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. ^ Occhiodoro T, Bernheim L, Liu JH, Bijlenga P, Sinnreich M, Bader CR, et al. (August 1998). "Cloning of a human ether-a-go-go potassium channel expressed in myoblasts at the onset of fusion". FEBS Letters. 434 (1–2): 177–182. Bibcode:1998FEBSL.434..177O. doi:10.1016/S0014-5793(98)00973-9 . PMID 9738473.
  6. ^ Gutman GA, Chandy KG, Grissmer S, Lazdunski M, McKinnon D, Pardo LA, et al. (December 2005). "International Union of Pharmacology. LIII. Nomenclature and molecular relationships of voltage-gated potassium channels". Pharmacological Reviews. 57 (4): 473–508. doi:10.1124/pr.57.4.10. PMID 16382104. S2CID 219195192.
  7. ^ a b "Entrez Gene: KCNH1 potassium voltage-gated channel, subfamily H (eag-related), member 1".
  8. ^ "603305 - Potassium channel, voltage-gated; subfamily H, member 1; KCNH1". Online Mendelian Inheritance in Man (OMIM).
  9. ^ Schmidt H, Farsi Z, Barrantes-Freer A, Rubio ME, Ufartes R, Eilers J, et al. (2015). "KV10.1 opposes activity-dependent increase in Ca2+ influx into the presynaptic terminal of the parallel fibre–Purkinje cell synapse". The Journal of Physiology. 593 (1): 181–196. doi:10.1113/jphysiol.2014.281600. ISSN 1469-7793. PMC 4293062 . PMID 25556795.
  10. ^ del Camino D, Sánchez A, Alves F, Brüggemann A, Beckh S, Stühmer W, et al. (1999年10月15日). "Oncogenic potential of EAG K+ channels". The EMBO Journal. 18 (20): 5540–5547. doi:10.1093/emboj/18.20.5540. ISSN 0261-4189. PMC 1171622 . PMID 10523298.
  11. ^ Gabbett MT, Clark RC, McGaughran JM (February 2008). "A second case of severe mental retardation and absent nails of hallux and pollex (Temple-Baraitser syndrome)". American Journal of Medical Genetics. Part A. 146A (4): 450–452. doi:10.1002/ajmg.a.32129. PMID 18203178. S2CID 2532859.
  12. ^ a b Simons C, Rash LD, Crawford J, Ma L, Cristofori-Armstrong B, Miller D, et al. (January 2015). "Mutations in the voltage-gated potassium channel gene KCNH1 cause Temple-Baraitser syndrome and epilepsy". Nature Genetics. 47 (1): 73–77. doi:10.1038/ng.3153. PMID 25420144. S2CID 52799681.
  13. ^ Kortüm F, Caputo V, Bauer CK, Stella L, Ciolfi A, Alawi M, et al. (June 2015). "Mutations in KCNH1 and ATP6V1B2 cause Zimmermann-Laband syndrome". Nature Genetics. 47 (6): 661–667. doi:10.1038/ng.3282. hdl:2108/118197 . PMID 25915598. S2CID 12060592.
  14. ^ Mégarbané A, Al-Ali R, Choucair N, Lek M, Wang E, Ladjimi M, et al. (June 2016). "Temple-Baraitser Syndrome and Zimmermann-Laband Syndrome: one clinical entity?". BMC Medical Genetics. 17 (1) 42. doi:10.1186/s12881-016-0304-4 . PMC 4901505 . PMID 27282200.
  15. ^ Bramswig NC, Ockeloen CW, Czeschik JC, van Essen AJ, Pfundt R, Smeitink J, et al. (October 2015). "'Splitting versus lumping': Temple-Baraitser and Zimmermann-Laband Syndromes". Human Genetics. 134 (10): 1089–1097. doi:10.1007/s00439-015-1590-1. PMID 26264464. S2CID 14238362.
  16. ^ Sundman AK, Jin S, Vadlamudi L, King GF (2025年09月23日). "The molecular basis of KCNH1-related epileptic encephalopathy and the challenge of developing targeted therapeutics". Brain. doi:10.1093/brain/awaf353. ISSN 0006-8950.
  17. ^ Tomczak AP, Zahed F, Stühmer W, Pardo LA, Urrego D (2014年03月19日). "Potassium channels in cell cycle and cell proliferation". Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences. 369 (1638) 20130094. doi:10.1098/rstb.2013.0094. PMC 3917348 . PMID 24493742.
  18. ^ Ottschytsch N, Raes A, Van Hoorick D, Snyders DJ (June 2002). "Obligatory heterotetramerization of three previously uncharacterized Kv channel alpha-subunits identified in the human genome". Proceedings of the National Academy of Sciences of the United States of America. 99 (12): 7986–7991. Bibcode:2002PNAS...99.7986O. doi:10.1073/pnas.122617999 . PMC 123007 . PMID 12060745.

Further reading

[edit ]
[edit ]
Classification

This article incorporates text from the United States National Library of Medicine, which is in the public domain.

Ligand-gated
Voltage-gated
Constitutively active
Proton-gated
Voltage-gated
Calcium-activated
Inward-rectifier
Tandem pore domain
Voltage-gated
Miscellaneous
Cl: Chloride channel
H+: Proton channel
M+: CNG cation channel
M+: TRP cation channel
H2O (+ solutes): Porin
Cytoplasm: Gap junction
By gating mechanism
Ion channel class
see also disorders

AltStyle によって変換されたページ (->オリジナル) /